ABOUT NEXUS ALLIANCE BIOPHARMACEUTICALS (NAB)
NAB is a late clinical-stage pharmaceutical company developing the proprietary use of specific conjugate delivery particles, delivered via a patented soluble particle of otherwise insoluble moiety, to increase the efficacy of the structure, reduce maximum therapeutic dose, and minimize dose limiting toxicity level of a known product. In short, it increases the efficacy, reduces the safety concerns while increases the life cycle use of the same product to adjacently progress the treatment of an underlying disease. NAB is currently preparing for a launching and approval of multiple products via 505 (B2) route as well as life cycle Phase III- type of Clinical Trials. We work with the top therapeutically decisive centres of excellence and have produced our publication in reflecting the positive Phase II Clinical Trial results.